These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9669405)

  • 41. A comparative study of renal scintigraphy and clearance with technetium-99m-MAG3 and iodine-123-hippurate in patients with renal disorders.
    Müller-Suur R; Bois-Svensson I; Mesko L
    J Nucl Med; 1990 Nov; 31(11):1811-7. PubMed ID: 2146371
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of technetium-99m-MAG3 in humans.
    Bubeck B; Brandau W; Weber E; Kälble T; Parekh N; Georgi P
    J Nucl Med; 1990 Aug; 31(8):1285-93. PubMed ID: 2143528
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of early postoperative MAG3 renal scan to predict long-term outcomes of renal transplants.
    Park UJ; Kim HT; Cho WH; Kim MY; Hwang EA; Han SY; Park SB; Kim HC; Zeon SK
    Exp Clin Transplant; 2013 Apr; 11(2):118-21. PubMed ID: 23477352
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Usefulness of renal dynamic function study with 99mTc-MAG3 (mercaptoacetylglycylglycylglycine)].
    Shirakawa S; Tamaki N; Torizuka T; Fujita T; Yano S; Tsuchimochi S; Yonekura Y; Konishi J; Terai A
    Kaku Igaku; 1994 Aug; 31(8):977-83. PubMed ID: 7933686
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of Tc-99m DTPA and Tc-99m MAG3 perfusion time-activity curves in patients with renal allograft dysfunction.
    Aktaş A; Aras M; Colak T; Gençoğlu A; Karakayali H
    Transplant Proc; 2006 Mar; 38(2):449-53. PubMed ID: 16549144
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of protein binding on renal extraction of 131I-OIH and 99mTc-labeled tubular agents.
    Eshima D; Eshima L; Hansen L; Lipowska M; Marzilli LG; Taylor A
    J Nucl Med; 2000 Dec; 41(12):2077-82. PubMed ID: 11138695
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pharmacokinetics of 99mTc-MAG3 and 131I-OIH: comparative study based on 2 compartment model analysis].
    Shuke N; Takashio T; Sato J; Ishikawa Y; Saito Y; Yamamoto W; Aburano T; Mizunaga M; Kaneko S; Yachiku S; Ogawa Y; Kikuchi K; Sasajima T; Kubo Y
    Kaku Igaku; 1996 May; 33(5):513-20. PubMed ID: 8699619
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Significance of early tubular extraction in the first minute of Tc-99m MAG3 renal transplant scintigraphy.
    Lin E; Alavi A
    Clin Nucl Med; 1998 Apr; 23(4):217-22. PubMed ID: 9554192
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative study of renal scintigraphy with 99Tcm-mercaptoacetyltriglycine and 123I-orthoiodohippurate.
    Itoh K; Tsukamoto E; Kakizaki H; Nonomura K; Furudate M
    Nucl Med Commun; 1993 Aug; 14(8):644-52. PubMed ID: 8371889
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical evaluation of technetium-99m-L,L-ethylenedicysteine in patients with chronic renal failure.
    Prvulovich EM; Bomanji JB; Waddington WA; Rudrasingham P; Verbruggen AM; Ell PJ
    J Nucl Med; 1997 May; 38(5):809-14. PubMed ID: 9170451
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The estimation of effective renal plasma flow (ERPF) based on two compartment analysis using 99mTc-mercaptoacetyltriglycine (99mTc-MAG3)].
    Ha-Kawa SK; Suga Y; Satou H; Tanaka Y
    Kaku Igaku; 1994 Feb; 31(2):175-81. PubMed ID: 8121073
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Phase 3 clinical study of 99mTc-MAG3 injectable, a dynamic renal imaging agent--comparison with 123I-OIH and 99mTc-DTPA].
    Torizuka K; Ishibashi A; Ikekubo K; Yamamoto K; Nishibuchi S
    Kaku Igaku; 1994 Feb; 31(2):183-98. PubMed ID: 8121074
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative study of the kinetics of the renal tracers 99Tcm-MAG3 and 131I-hippuran.
    Pavía J; Ros D; Piera C; Pavía A; Bassa P; Giralt E; Setoain J
    Nucl Med Commun; 1991 Jun; 12(6):529-37. PubMed ID: 1830943
    [TBL] [Abstract][Full Text] [Related]  

  • 54. How gender and age affect iodine-131-OIH and technetium-99m-MAG3 clearance.
    Bagni B; Bagni I; Orsolon P; Corazzari T
    J Nucl Med Technol; 2000 Sep; 28(3):156-8. PubMed ID: 11001496
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quantitation of renal parenchymal retention of technetium-99m-MAG3 in renal transplants.
    Li Y; Russell CD; Palmer-Lawrence J; Dubovsky EV
    J Nucl Med; 1994 May; 35(5):846-50. PubMed ID: 8176469
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimum sample times for single-injection, multisample renal clearance methods.
    Russell CD
    J Nucl Med; 1993 Oct; 34(10):1761-5. PubMed ID: 8410295
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of single-injection multisample renal clearance methods with and without urine collection.
    Russell CD; Dubovsky EV
    J Nucl Med; 1995 Apr; 36(4):603-6. PubMed ID: 7699449
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the clearance of technetium-99m MAG3 and iodine-131 OIH.
    Kim CK; Stritzke P; Goldsmith SJ
    J Nucl Med; 1988 Nov; 29(11):1878-9. PubMed ID: 2972816
    [No Abstract]   [Full Text] [Related]  

  • 59. MAG3 renogram deconvolution in kidney transplantation: utility of the measurement of initial tracer uptake.
    Bajén MT; Puchal R; González A; Grinyó JM; Castelao A; Mora J; Martin-Comin J
    J Nucl Med; 1997 Aug; 38(8):1295-9. PubMed ID: 9255171
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Simultaneous technetium-99 MAG(3), iodine-131-orthoiodohippurate and iodine-125 iothalamate clearance and biodistribution after bolus injection in rats.
    Casadevall G; Turull A; Piera C; Queralt J
    Biopharm Drug Dispos; 2000 Jul; 21(5):181-92. PubMed ID: 11180197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.